The emphasis on mechanisms driving multiple sclerosis (MS) symptomatic worsening
suggests that we move beyond categorical clinical classifiers such as relapsing–remitting …

Importance Early treatment initiation in multiple sclerosis (MS) is crucial in preventing
irreversible neurological damage and disability progression. The current assessment of …

In vitro investigations have revealed that consumption of selenium can considerably
decrease the expression of IFN-g in Th1 cells. A low plasma selenium content has been …

Multiple sclerosis is an important neurological disease affecting millions of young patients
globally. It is encouraging that more than ten disease-modifying drugs became available for …

The emergence of high-efficacy therapies for multiple sclerosis (MS), which target
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …

Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …

Background and objectives: Alemtuzumab demonstrated superior efficacy versus
subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple …

Numerous therapies are currently available to modify the disease course of multiple
sclerosis (MS). Magnetic resonance imaging (MRI) plays a pivotal role in assessing …

Background Dimethyl fumarate (DMF) is a common treatment for multiple sclerosis (MS), but
its mechanisms of action are not fully understood. Targeted proteomics offers insights into …

Despite the pharmacological arsenal approved for Multiple Sclerosis (MS), there are
treatment-reluctant patients for whom cell therapy appears as the only therapeutic …